The Company continues to engage with convertible bondholders and right-size the capital structure through these exchanges ... improvement in the primary endpoint of event-free... at 10:35 KEYTRUDA® ...

Summit's ivonescimab outperforms Keytruda in lung cancer trial, positioning the company to capture a significant market share ...

Recommended Reading A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology An experimental medicine from a small biotechnology company cut the risk of lung cancer ...

AI and biophysics are revolutionizing cancer treatment by predicting protein binding sites for personalized therapies.

Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...

It will also evaluate the impact of the subretinal administration of OpCT-001 on retinal structure, visual function, and functional vision in individuals. The study is set to explore various dose ...

At the same time, the commentary by Tom Long - Co-Chief Executive Officer - indicated a continued focus on preserving the high quality of the capital structure as the projected CapEx spend for ...

(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab ...

Merck MRK decided to discontinue two separate phase III studies, KEYNOTE-867 and KEYNOTE-630, evaluating its blockbuster drug Keytruda in patients with certain types of lung cancer and skin cancer ...

London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

Mer­ck said Thurs­day morn­ing it is dis­con­tin­u­ing two Phase 3 tri­als of Keytru­da, the world’s top-sell­ing med­i­cine, af­ter in­de­pen­dent da­ta mon­i­tor­ing … ...